TY - JOUR
T1 - Baseline Characteristics of Participants in STAREE
T2 - A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People
AU - STAREE Investigator Group
AU - Zoungas, Sophia
AU - Moran, Chris
AU - Curtis, Andrea J.
AU - Spark, Simone
AU - Flanagan, Zachary
AU - Beilin, Lawrence
AU - Chong, Trevor T.J.
AU - Cloud, Geoffrey C.
AU - Hopper, Ingrid
AU - Kost, Alissia
AU - McNeil, John J.
AU - Nicholls, Stephen J.
AU - Reid, Christopher M.
AU - Ryan, Joanne
AU - Tonkin, Andrew M.
AU - Ward, Stephanie
AU - Wierzbicki, Anthony S.
AU - Wolfe, Rory
AU - Zhou, Zhen
AU - Nelson, Mark R.
PY - 2024/11/19
Y1 - 2024/11/19
N2 - BACKGROUND: The risk-benefit balance of statin use in healthy older people is uncertain. We describe the baseline characteristics of the STAREE (Statins in Reducing Events in the Elderly) trial, which is a randomized, double-blind, placebo-controlled trial among community-dwelling older people; the trial evaluated the effect of atorvastatin 40 mg for the prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction or stroke), and on disability-free survival (survival free of both dementia and persistent physical disability). METHODS AND RESULTS: STAREE enrolled people aged ≥70 years from 1583 general practices across Australia with no history of clinical cardiovascular disease, diabetes, or dementia. Baseline data collected included demographic, clinical, cognitive (Modified Mini-Mental State Examination), psychological (Center for Epidemiologic Studies Short Depression Scale), lifestyle, medical, physical, blood and urine measures, and quality of life. Demographic and clinical characteristics of study participants were then compared with publicly available landmark statin trials. A total of 9971 participants were recruited (mean±SD age 74.7±4.5 years, 4023 (40%) ≥75 years, 52% women) between July 2015 and March 2023. The mean low-density lipoprotein cholesterol was 3.27 mmol/L (SD=0.72; 126 mg/dL). Hypertension was reported by 43% of participants and the mean blood pressure was 136/80 mm Hg. Compared with previous landmark statin trials that included primary prevention cohorts, STAREE is unique in including such a large number of older (≥75 years) independent-living people. CONCLUSIONS: STAREE is the largest primary prevention trial of statins powered to address the important clinical outcomes of major cardiovascular events, disability-free survival, and cognition in older people. REGISTRATION: https://www.clinicaltrials.gov; Unique identifier: NCT02099123.
AB - BACKGROUND: The risk-benefit balance of statin use in healthy older people is uncertain. We describe the baseline characteristics of the STAREE (Statins in Reducing Events in the Elderly) trial, which is a randomized, double-blind, placebo-controlled trial among community-dwelling older people; the trial evaluated the effect of atorvastatin 40 mg for the prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction or stroke), and on disability-free survival (survival free of both dementia and persistent physical disability). METHODS AND RESULTS: STAREE enrolled people aged ≥70 years from 1583 general practices across Australia with no history of clinical cardiovascular disease, diabetes, or dementia. Baseline data collected included demographic, clinical, cognitive (Modified Mini-Mental State Examination), psychological (Center for Epidemiologic Studies Short Depression Scale), lifestyle, medical, physical, blood and urine measures, and quality of life. Demographic and clinical characteristics of study participants were then compared with publicly available landmark statin trials. A total of 9971 participants were recruited (mean±SD age 74.7±4.5 years, 4023 (40%) ≥75 years, 52% women) between July 2015 and March 2023. The mean low-density lipoprotein cholesterol was 3.27 mmol/L (SD=0.72; 126 mg/dL). Hypertension was reported by 43% of participants and the mean blood pressure was 136/80 mm Hg. Compared with previous landmark statin trials that included primary prevention cohorts, STAREE is unique in including such a large number of older (≥75 years) independent-living people. CONCLUSIONS: STAREE is the largest primary prevention trial of statins powered to address the important clinical outcomes of major cardiovascular events, disability-free survival, and cognition in older people. REGISTRATION: https://www.clinicaltrials.gov; Unique identifier: NCT02099123.
KW - primary prevention
KW - randomized clinical trial
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=85210105942&partnerID=8YFLogxK
U2 - 10.1161/JAHA.124.036357
DO - 10.1161/JAHA.124.036357
M3 - Article
C2 - 39548016
AN - SCOPUS:85210105942
SN - 2047-9980
VL - 13
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 22
M1 - e036357
ER -